Loading...

SEPN SEPTERNA INC Product Launches 8-K Filing

SPTR

SPN

SEPTERNA INC

(SEPN)

2025 8-K

Show Summary

Summary

Investor Presentation Update

Clinical Trial Announcement

Financial Statements

Financial Results

Investor Meetings

Trial Discontinuation

Investor Conference

CFO Appointment

Financial Results

Incorporation Changes

External Links:

Septerna Inc. announced the discontinuation of its SEP-786 Phase 1 clinical trial and plans to focus on developing a next-generation oral small molecule PTH1R agonist.

AI Assistant

SEPTERNA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.